Table 5.
Effects of gentamycin induced testicular damage and pioglitazone treatment on sperm parameters.
| Group | GI (n = 10) | GII (n = 10) | GIII (n = 10) | GIV (n = 10) | GV (n = 10) |
|---|---|---|---|---|---|
| Sperm count (×106) | 62.23 ± 0.88 bcd | 4.97 ± 0.37 acde | 54.28 ± 0.44 be | 55.85 ± 0.52 abe | 60.18 ± 0.56 bcd |
| Sperm motility (%) | 84.22 ± 0.78 | 65.37 ± 0.91 a | 72.89 ± 0.91 b | 78.57 ± 0.43 b | 82.85 ± 0.89 b |
| Sperm viability (%) | 80.6 ± 1.71 | 59.69 ± 0.32 a | 65.58 ± 0.58 b | 71.6 ± 0.96 b | 76.20 ± 1.67 b |
GI: CTL, normal control, GII: GM, gentamycin induced testicular damage, GIII: PIO 5 pioglitazone treated (5 mg/kg/day), GIV: PIO 10 pioglitazone treated (10 mg/kg/day) and GV: PIO 20 pioglitazone treated (20 mg/kg/day). Values are expressed as mean ± SEM, (a) compared to control group (GI), (b) compared to GM treated group (GII), (c) compared to PIO 5 (GIII) group, (d) compared to PIO 10 (G IV) group, (e) compared to PIO 20 (GV) group.